ClinicalTrials.gg
CompletedNCT00539669Updated Oct 4, 2007

TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian

A Phase 2 interventional study of Docetaxel in Ovarian Neoplasms, sponsored by Sanofi. Completed at 1 site in Korea, Republic of. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-10-04.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 38 studies testing docetaxel in Ovarian Neoplasms — none open to participants now, none under way, none of them phase 3. Docetaxel · Ovarian Neoplasms.

Enrollment
9th of 32
47 · median 34
Started
2003
with 7 others
Phase 2
23 of 38
none open now
Registered
28th of 38
by date
Lead sponsor
3 of 38
Sanofi

Among the 38 studies testing docetaxel in Ovarian Neoplasms, this one is the 9th largest by enrollment of the 32 interventional ones that give a count, is one of 8 that started in 2003, is one of 23 in phase 2, and was the 28th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 38 studies testing docetaxel in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 38 studies testing docetaxel in Ovarian Neoplasms as a file.
02

Study summary

Evaluate response rate of Docetaxel in combination with Carboplatin or Cisplatin as first line chemotherapy in epithelial ovarian cancer. Assess the progression free survival, tolerance, duration of response and survival in the same patient population.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed epithelial ovarian carcinoma. Patients with peritoneal carcinomatosis are also eligible, without necessarily having histological proof of a primary source in the ovary, provided that the tumour is not mucin-secreting, and that there is no evidence of a primary fallopian tube cancer (see exclusion criteria).
  • Female, aged 18 or over- FIGO stages Ic-IV with or without successful cytoreductive surgery at staging laparotomy. Stage Ic patients will be limited to those with malignant cells in ascitic fluid, peritoneal washings or with tumour on the surface of the ovary
  • Patients with ruptured capsule as the only evidence of stage Ic will not be eligible for entry into the study.

Exclusion criteria

Exclusion Criteria:

  • performance status > 2
  • Prior treatment with chemotherapy or radiotherapy.
  • Patients with, pre-existing fluid retention such as pleural effusion, pericardial effusion and ascites are not excluded from the study, but should be monitored closely for any deterioration. Efforts should be made to determine by cytological analysis whether any significant pre-existing fluid collections are due to ovarian cancer, and subsequent drainage is recommended before initiating chemotherapy.
  • Inadequate bone marrow function defined as neutrophils \< 1.5 x 109/l or \< 100 x 109/l.
  • Inadequate renal function as defined by serum creatinine > 1.25 x .
  • Inadequate liver function as defined by > upper limit of normal or /ALT > 1.5 x upper limit of normal or ALP > 3 x upper limit of normal.
  • Concurrent severe and/or uncontrolled co-morbid medical condition (i.e. uncontrolled infection, hypertension, ischaemic heart disease, myocardial infarction within previous 6 months, congestive heart failure)
  • Patients with mixed mesodermal tumours.
  • Patients with borderline ovarian tumours or tumours termed 'possibly malignant'.
  • Adenocarcinoma of unknown origin, if histologically shown to be mucin-secreting cancer or thought to be possible primary fallopian tube carcinoma.
  • History of previous within the previous 5 years (except curatively treated carcinoma in situ of the uterine cervix, or basal cell carcinoma of the skin), or concurrent malignancy (e.g. coexisting endometrial cancer) .
  • History of prior serious allergic reactions (e.g. anaphylactic shock).
  • History of other relative to administration
  • Pregnant or lactating women (or potentially fertile women not using adequate ).
  • Symptomatic peripheral neuropathy > NCIC-CTC grade II.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The response rate will be determined by the number of patients with complete and partial responses according to the Modified SWOG Response Criteria. The progression free survival, duration of response and survival are evaluated.

07

Study locations

1 site
  • Sanofi-Aventis
    Seoul, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 4, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00539669
Lead sponsor
Sanofi
First posted
Oct 4, 2007
Start date
Mar 2003
Last update
Oct 4, 2007

Study contacts

Hyang Rim Kim
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion